依洛尤单抗联合瑞舒伐他汀对高胆固醇血症患者血脂谱的影响及安全性分析

Effect and Safety of Evolocumab Combined with Rosuvastatin Regarding Serum Lipid Profile in Patients with Hypercholesterolemia

目的:探讨依洛尤单抗联合瑞舒伐他汀对经饮食控制和非药物治疗后血脂水平仍不达标的高胆固醇血症患者血脂水平的影响及安全性分析。方法:回顾性选取2019年1月~2021年5月期间于某院住院治疗的80例经饮食控制和非药物治疗后血脂水平仍不达标的高胆固醇血症患者作为研究对象,根据治疗方式不同分为对照组(n=30)和观察组(n=50)。对照组患者给予瑞舒伐他汀钙片治疗,观察组在对照组基础上加用依洛尤单抗注射液,两组均连续治疗2个月。比较两组患者血脂指标[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)]水平、临床疗效及治疗期间不良反应的发生情况。结果:治疗后,观察组患者TC、TG、LDL-C及ApoB水平均低于对照组(P<0.05),HDL-C水平高于对照组(P<0.05)。观察组患者治疗总有效率(94.00%)高于对照组(73.33%,P<0.05)。两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:在瑞舒伐他汀钙片调脂治疗基础上联合依洛尤单抗注射液治疗可有效调节患者的血脂水平,且未增加不良反应的发生风险。

Objective:To investigate the effect and safety of evolocumab combined with rosuvastatin on serum lipid levels in patients with hypercholesterolemia whose blood lipid levels were uncontrolled despite dietary control and non-drug therapy.Methods:80 patients with hypercholesterolemia,whose serum lipid levels were uncontrolled despite dietary control and non-drug therapy,were selected retrospectively from January 2019 to May 2021 and divided into the control group(n=30)and the observation group(n=50)according to treatment approaches.The control group was treated with rosuvastatin calcium tablets,the observation group was treated with evolocumab injection in addition to the treatment given in the control group,and both groups were treated continuously for 2 months.The levels of serum lipid parameters[total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),apolipoprotein A1(ApoA1),apolipoprotein B(ApoB)],clinical effect and the occurrence of treatment-emergent adverse reactions were compared between the two groups.Results:After treatment,the levels of TC,TG,LDL-C and ApoB in the observation group were lower than those of the control group(P<0.05),while the level of HDL-C was higher than that of the control group(P<0.05).The total effective rate of observation group(94.00%)was higher than that of the control group(73.33%,P<0.05).No statistically significant difference was observed in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of rosuvastatin,the conventional lipid-lowering therapy,with evolocumab can effectively regulate the serum lipid levels without additional risks of adverse reactions.